{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:41:58Z","timestamp":1788982918536,"version":"build-2803163510"},"reference-count":176,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Myasthenia gravis (MG) has traditionally been conceptualized as a peripheral autoimmune disorder primarily mediated by autoantibodies targeting the neuromuscular junction. However, this classical paradigm fails to adequately explain the prevalent central nervous system (CNS) manifestations in patients, including profound fatigue and cognitive impairment. Emerging evidence indicates that neuroinflammation plays a pivotal role in bridging peripheral pathology and central symptoms. Systemic inflammatory mediators can breach the compromised blood-brain barrier (BBB) or activate CNS-resident microglia and astrocytes via neuroimmune pathways, thereby initiating neuroinflammatory cascades. Once activated, these glial cells release pro-inflammatory cytokines and reactive oxygen species (ROS), which impair neuronal energy metabolism, synaptic plasticity, and neurotransmitter homeostasis, directly contributing to central symptomatology. Critically, neuroinflammation serves as a key mechanistic bridge linking the peripheral autoimmune pathology of MG with age-related neurodegenerative changes. With advancing age, immunosenescence manifests as diminished T-cell repertoire diversity, impaired regulatory T-cell function, and chronic low-grade inflammation (inflammaging), which not only increases susceptibility to MG but also provides a permissive environment for the initiation and perpetuation of neuroinflammation. Concurrently, age-related degenerative alterations at the neuromuscular junction\u2014including reduced acetylcholine receptor (AChR) density and mitochondrial dysfunction\u2014decrease the safety margin of neuromuscular transmission, rendering elderly patients more vulnerable to autoantibody-mediated attack. A vicious cycle emerges among neuroinflammation, mitochondrial dysfunction, and oxidative stress, which synergistically accelerate neuronal damage and apoptosis. Consequently, the clinical phenotype, therapeutic response, and prognosis of MG demonstrate marked age-dependency. Late-onset MG patients typically experience more severe disease courses and poorer outcomes, attributable in part to the compounding effects of immunosenescence, underlying neurodegeneration, and neuroinflammation. Elucidating the central role of neuroinflammation and its intricate interactions with age-related pathological processes holds significant theoretical and clinical implications for developing novel neuroprotective strategies targeting CNS symptoms in MG and achieving personalized, precision medicine tailored to patients across different age groups.<\/jats:p>","DOI":"10.3389\/fmed.2026.1746161","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:19:40Z","timestamp":1777609180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Neuroinflammation: a critical bridge linking peripheral pathology and age-related degeneration in myasthenia gravis"],"prefix":"10.3389","volume":"13","author":[{"given":"Fan-yu","family":"Liu","sequence":"first","affiliation":[{"name":"Liaoning University of Traditional Chinese Medicine","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-peng","family":"Huang","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-qing","family":"Li","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-sheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Guan","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-jun","family":"Qiao","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategiesc","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"577634","DOI":"10.1016\/j.jneuroim.2021.577634","article-title":"High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis","volume":"358","author":"Uzawa","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"eadm7908","DOI":"10.1126\/sciimmunol.adm7908","article-title":"Infection and chronic disease activate a systemic brain-muscle signaling axis","volume":"9","author":"Yang","year":"2024","journal-title":"Sci Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J Med Life"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","article-title":"The blood-brain barrier in systemic inflammation","volume":"60","author":"Varatharaj","year":"2017","journal-title":"Brain Behav Immun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41593-020-00783-4","article-title":"Reactive astrocyte nomenclature, definitions, and future directions","volume":"24","author":"Escartin","year":"2021","journal-title":"Nat Neurosci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nrn3898","article-title":"Astrocyte barriers to neurotoxic inflammation","volume":"16","author":"Sofroniew","year":"2015","journal-title":"Nat Rev Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"661838","DOI":"10.3389\/fncel.2021.661838","article-title":"Blood-brain barrier dysfunction amplifies the development of neuroinflammation: understanding of cellular events in brain microvascular endothelial cells for prevention and treatment of BBB Dysfunction Front Cell Neurosci","volume":"15","author":"Takata","year":"2021"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.4049\/jimmunol.1103460","article-title":"Role of caspases in cytokine-induced barrier breakdown in human brain endothelial cells","volume":"189","author":"Lopez-Ramirez","year":"2012","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm1651","article-title":"Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation","volume":"13","author":"Kebir","year":"2007","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/brain\/awm295","article-title":"The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells","volume":"131","author":"Ifergan","year":"2008","journal-title":"Brain"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/eji.201445125","article-title":"Cell surface levels of endothelial ICAM-1 influence the transcellular or paracellular T-cell diapedesis across the blood-brain barrier","volume":"45","author":"Abadier","year":"2015","journal-title":"Eur J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.nicl.2014.09.002","article-title":"Assessment of blood\u2013brain barrier disruption using dynamic contrast-enhanced MRI a systematic review","volume":"6","author":"Heye","year":"2014","journal-title":"NeuroImage"},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0022-510X(87)90217-6","article-title":"Immunoactivation in the central nervous system in myasthenia gravis","volume":"80","author":"M\u00fcller","year":"1987","journal-title":"J Neurol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41590-021-00927-z","article-title":"Hallmarks of T cell aging","volume":"22","author":"Mittelbrunn","year":"2021","journal-title":"Nat Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14863","DOI":"10.1073\/pnas.1002220107","article-title":"Attenuation of age-related changes in mouse neuromuscular synapses by caloric restriction and exercise","volume":"107","author":"Valdez","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?","volume":"17","author":"Leng","year":"2021","journal-title":"Nat Rev Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1117172","DOI":"10.3389\/fimmu.2023.1117172","article-title":"The effects of microglia-associated neuroinflammation on Alzheimer's disease","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2465410","DOI":"10.1080\/08916934.2025.2465410","article-title":"Mitochondrial autophagy-related gene signatures associated with myasthenia gravis diagnosis and immunity","volume":"58","author":"Jin","year":"2025","journal-title":"Autoimmunity"},{"key":"B21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","article-title":"Mitochondria as multifaceted regulators of cell death","volume":"21","author":"Bock","year":"2020","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12601","article-title":"High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair","volume":"280","author":"Bianchi","year":"2017","journal-title":"Immunol Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/bs.irn.2025.04.024","article-title":"Autoantibodies in myasthenia gravis","volume":"182","author":"Fichtner","year":"2025","journal-title":"Int Rev Neurobiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"831","DOI":"10.11477\/mf.1416202428","volume":"75","author":"Uzawa","year":"2023","journal-title":"Brain Nerve."},{"key":"B25","doi-asserted-by":"publisher","first-page":"596981","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/bs.irn.2025.04.035","article-title":"Contribution of cellular immune dysregulation to myasthenia gravis pathology","volume":"182","author":"Bayer","year":"2025","journal-title":"Int Rev Neurobiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/rheumatology\/kez077","article-title":"Expanded circulating peripheral helper T cells in systemic lupus erythematosus: association with disease activity and B cell differentiation","volume":"58","author":"Makiyama","year":"2019","journal-title":"Rheumatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"578464","DOI":"10.1016\/j.jneuroim.2024.578464","article-title":"Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients","volume":"396","author":"Li","year":"2024","journal-title":"J Neuroimmunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaut.2013.12.018","article-title":"Thymoma-associated myasthenia gravis: on the search for a pathogen signature","volume":"52","author":"Cufi","year":"2014","journal-title":"J Autoimmun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/nature06066","article-title":"An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus","volume":"448","author":"Giraud","year":"2007","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/WCO.0b013e328364d6cd","article-title":"Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation","volume":"26","author":"Le Panse","year":"2013","journal-title":"Curr Opin Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1126\/science.1075958","article-title":"Projection of an immunological self shadow within the thymus by the aire protein","volume":"298","author":"Anderson","year":"2002","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: from mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"109173","DOI":"10.1016\/j.clim.2022.109173","article-title":"Gut microbiota and metabolites in myasthenia gravis: early diagnostic biomarkers and therapeutic strategies","volume":"245","author":"Kang","year":"2022","journal-title":"Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"Ns20210035","DOI":"10.1042\/NS20210035","article-title":"Cholinergic blockade of neuroinflammation: from tissue to RNA regulators","volume":"6","author":"Zorbaz","year":"2022","journal-title":"Neuronal Signal."},{"key":"B40","doi-asserted-by":"publisher","first-page":"110988","DOI":"10.1016\/j.brainresbull.2024.110988","article-title":"SOCS modulates JAK-STAT pathway as a novel target to mediate the occurrence of neuroinflammation: molecular details and treatment options","volume":"213","author":"Yan","year":"2024","journal-title":"Brain Res Bull"},{"key":"B41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.31083\/j.fbl2811306","article-title":"Serum Pentaxin 3 (PTX3) promotes NLRP3 inflammasome and pyroptosis in patients with up-regulated myasthenia gravis","volume":"28","author":"Li","year":"2023","journal-title":"Front Biosci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"374","DOI":"10.7150\/thno.74831","article-title":"Ablation of NLRP3 inflammasome attenuates muscle atrophy via inhibiting pyroptosis, proteolysis and apoptosis following denervation","volume":"13","author":"You","year":"2023","journal-title":"Theranostics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1400533","DOI":"10.3389\/fimmu.2024.1400533","article-title":"The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions","volume":"15","author":"Kerkis","year":"2024","journal-title":"Front Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.2174\/1570159X21666221129121715","article-title":"Bidirectional communication between microglia and astrocytes in neuroinflammation","volume":"21","author":"Bhusal","year":"2023","journal-title":"Curr Neuropharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature."},{"key":"B46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes","volume":"9","author":"Sung","year":"2020","journal-title":"Transl Neurodegener."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","article-title":"Differential Roles of M1 and M2 Microglia in neurodegenerative diseases","volume":"53","author":"Tang","year":"2016","journal-title":"Mol Neurobiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"101013","DOI":"10.1016\/j.bbih.2025.101013","article-title":"Systematic review and meta-analysis of microbiota-gut-astrocyte axis perturbation in neurodegeneration, brain injury, and mood disorders","volume":"46","author":"Radford-Smith","year":"2025","journal-title":"Brain Behav Immun Health"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1575453","DOI":"10.3389\/fnins.2025.1575453","article-title":"The roles of microglia and astrocytes in neuroinflammation of Alzheimer's disease","volume":"19","author":"Han","year":"2025","journal-title":"Front Neurosci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2174\/18756190MTE54MTYyy","article-title":"Neuroinflammation in Huntington's disease: a starring role for astrocyte and microglia","volume":"20","author":"Saba","year":"2022","journal-title":"Curr Neuropharmacol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1756286418799864","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you \u2018take the brakes off' the immune system","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24976\/Discov.Med.202537192.1","article-title":"Neuroinflammation in the post-ischemic brain in the presence of amyloid and tau protein","volume":"37","author":"Pluta","year":"2025","journal-title":"Discov Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1501359","DOI":"10.3389\/fsurg.2025.1501359","article-title":"Neuroinflammation and acute ischemic stroke: impact on translational research and clinical care","volume":"12","author":"Levinson","year":"2025","journal-title":"Front Surg."},{"key":"B54","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s43018-023-00519-w","article-title":"Reciprocal interactions between innate immune cells and astrocytes facilitate neuroinflammation and brain metastasis via lipocalin-2","volume":"4","author":"Adler","year":"2023","journal-title":"Nat Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/imr.13081","article-title":"Osteopontin\/secreted phosphoprotein-1 harnesses glial-, immune-, and neuronal cell ligand-receptor interactions to sense and regulate acute and chronic neuroinflammation","volume":"311","author":"Yim","year":"2022","journal-title":"Immunol Rev."},{"key":"B56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10522-025-10252-9","article-title":"The age-dependent neuroglial interaction with peripheral immune cells in coronavirus-induced neuroinflammation with a special emphasis on COVID-19","volume":"26","author":"Ghosh","year":"2025","journal-title":"Biogerontology."},{"key":"B57","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00011-025-02048-x","article-title":"Interleukin-37 modulates microglial phenotype and inhibits inflammatory response via the MyD88\/NF-\u03baB pathway in lipopolysaccharide-induced neuroinflammation","volume":"74","author":"Zhang","year":"2025","journal-title":"Inflamm Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1172\/JCI141964","article-title":"Macrophage monocarboxylate transporter 1 promotes peripheral nerve regeneration after injury in mice","author":"Jha","year":"2021","journal-title":"J Clin Invest"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3390\/cells13231945","article-title":"Neuronal cell rearrangement during aging: antioxidant compounds as a potential therapeutic approach","volume":"13","author":"Bej","year":"2024","journal-title":"Cells"},{"key":"B60","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/ibra.12106","article-title":"Aging-related histone modification changes in brain function","volume":"9","author":"Ding","year":"2023","journal-title":"Ibrain."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2025.05.002","article-title":"Processivity and BDNF-dependent modulation of signalling endosome axonal transport are impaired in mice with advanced age","volume":"153","author":"Villarroel-Campos","year":"2025","journal-title":"Neurobiol Aging"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3390\/cells12192348","article-title":"Hydrocortisone mitigates Alzheimer's-related cognitive decline through modulating oxidative stress and neuroinflammation","volume":"12","author":"Li","year":"2023","journal-title":"Cells"},{"key":"B63","doi-asserted-by":"publisher","first-page":"111675","DOI":"10.1016\/j.mad.2022.111675","article-title":"Cellular senescence in the aging brain: a promising target for neurodegenerative diseases","volume":"204","author":"Sahu","year":"2022","journal-title":"Mech Ageing Dev"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.3390\/nu14153012","article-title":"Tea polyphenols as prospective natural attenuators of brain aging","volume":"14","author":"Hong","year":"2022","journal-title":"Nutrients"},{"key":"B65","doi-asserted-by":"publisher","first-page":"110225","DOI":"10.1016\/j.jbc.2025.110225","article-title":"Microglial TAK1 promotes neurotoxic astrocytes and cognitive impairment in LPS-induced hippocampal neuroinflammation","volume":"301","author":"Han","year":"2025","journal-title":"J Biol Chem"},{"key":"B66","doi-asserted-by":"publisher","first-page":"8369","DOI":"10.3390\/ijms26178369","article-title":"Idiopathic inflammatory myopathy-molecular mechanisms underlying its pathogenesis and physical therapy effects","volume":"26","author":"Markowska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/jcph.2187","article-title":"Characterization of immune checkpoint inhibitor-induced myasthenia gravis using the US food and drug administration adverse event reporting system","volume":"63","author":"Niimura","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/pharmaceutics16050651","article-title":"Nanodrug delivery systems for myasthenia gravis: advances and perspectives","volume":"16","author":"Huang","year":"2024","journal-title":"Pharmaceutics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"27118","DOI":"10.31083\/FBL27118","article-title":"Ignoring Gender-based immunometabolic reprograming, a risky business in immune-based precision medicine","volume":"30","author":"Kumar","year":"2025","journal-title":"Front Biosci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"9203","DOI":"10.1073\/pnas.97.16.9203","article-title":"T cell homeostasis in patients with rheumatoid arthritis","volume":"97","author":"Koetz","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"B71","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3389\/fimmu.2020.00240","article-title":"New approaches to targeting B cells for myasthenia gravis therapy","volume":"11","author":"Ruksana","year":"2020","journal-title":"Front Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e29379","DOI":"10.7759\/cureus.29379","article-title":"Overlapping autoimmune neurological syndrome: a case report of triple-positive antibody","volume":"14","author":"Bonner","year":"2022","journal-title":"Cureus."},{"key":"B73","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging an evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archneur.56.1.25","article-title":"Late-onset myasthenia gravis: a changing scene","volume":"56","author":"Aarli","year":"1999","journal-title":"Arch Neurol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"S422","DOI":"10.1513\/AnnalsATS.201602-095AW","article-title":"Aging of the immune system. mechanisms and therapeutic targets","volume":"13","author":"Weyand","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"B76","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2567.2011.03470.x","article-title":"CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease","volume":"134","author":"Marius","year":"2011","journal-title":"Immunology."},{"key":"B77","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.molmed.2012.06.003","article-title":"Pathogenic features of CD4 + CD28 \u2013 T cells in immune disorders","volume":"18","author":"Broux","year":"2012","journal-title":"Trends Mol Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000097202","article-title":"Passage of cytokines across the blood-brain barrier","volume":"2","author":"Banks","year":"1995","journal-title":"Neuroimmunomodulation."},{"key":"B79","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4 + CD25 high CD127 low\/\u2013 T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clin Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1126\/science.aab3389","article-title":"Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection","volume":"350","author":"Blackburn","year":"2015","journal-title":"Science."},{"key":"B81","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1038\/ncomms5172","article-title":"Chronic inflammation induces telomere dysfunction and accelerates ageing in mice","volume":"2","author":"Jurk","year":"2014","journal-title":"Nat Commun"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2014.05.001","article-title":"Myasthenia gravis: paradox versus paradigm in autoimmunity","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B83","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41593-024-01610-w","article-title":"TREM1 disrupts myeloid bioenergetics and cognitive function in aging and Alzheimer disease mouse models","volume":"27","author":"Wilson","year":"2024","journal-title":"Nat Neurosci"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.3390\/ijms24043073","article-title":"Relationship between hypoxic and immune pathways activation in the progression of neuroinflammation: role of HIF-1\u03b1 and Th17 cells","volume":"24","author":"Arias","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B85","doi-asserted-by":"publisher","first-page":"106158","DOI":"10.1016\/j.bbi.2025.106158","article-title":"Galectin-9 activates the TLR4-NLRP3 inflammasome pathway and promotes tau pathology in Alzheimer's disease","author":"Guo","year":"2025","journal-title":"Brain Behav Immun"},{"key":"B86","doi-asserted-by":"publisher","first-page":"107908","DOI":"10.1016\/j.phrs.2025.107908","article-title":"Exosome-mediated microglia-astrocyte interactions drive neuroinflammation in Parkinson's disease with Peli1 as a potential therapeutic target","volume":"219","author":"Guo","year":"2025","journal-title":"Pharmacol Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1007\/s12035-021-02518-3","article-title":"Fyn kinase activity and its role in neurodegenerative disease pathology: a potential universal target?","volume":"58","author":"Guglietti","year":"2021","journal-title":"Mol Neurobiol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"577912","DOI":"10.3389\/fncel.2020.577912","article-title":"Cholinergic modulation of glial function during aging and chronic neuroinflammation","volume":"14","author":"Gamage","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.1542\/peds.2013-0814","article-title":"Clinical characteristics of pediatric myasthenia: a surveillance study","volume":"132","author":"VanderPluym","year":"2013","journal-title":"Pediatrics"},{"key":"B92","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0960-8966(98)00077-7","article-title":"Juvenile myasthenia gravis with prepubertal onset","volume":"8","author":"Evoli","year":"1998","journal-title":"Neuromuscul Disord"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1212\/WNL.44.7.1208","article-title":"Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis","volume":"44","author":"Andrews","year":"1994","journal-title":"Neurology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet."},{"key":"B95","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B98","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"B99","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J Neurol Sci"},{"key":"B100","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"49","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"B101","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.medcle.2023.04.012","article-title":"Myasthenia gravis. Update on diagnosis and therapy","volume":"161","author":"Garc\u00eda Est\u00e9vez","year":"2023","journal-title":"Med Clin."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1212\/01.WNL.0000050461.05432.C5","article-title":"Myasthenia gravis: a higher than expected incidence in the elderly","volume":"60","author":"Aragon\u00e8s","year":"2003","journal-title":"Neurology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/jnnp.2005.072355","article-title":"Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001","volume":"77","author":"Owe","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/ni.2588","article-title":"Understanding immunosenescence to improve responses to vaccines","volume":"14","author":"Goronzy","year":"2013","journal-title":"Nat Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"B108","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.exger.2010.08.029","article-title":"Age-associated alterations of the neuromuscular junction","volume":"46","author":"Jang","year":"2011","journal-title":"Exp Gerontol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1001\/archneur.57.11.1596","article-title":"The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies","volume":"57","author":"Romi","year":"2000","journal-title":"Arch Neurol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1046\/j.1468-1331.2003.00678.x","article-title":"Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study","volume":"10","author":"Romi","year":"2003","journal-title":"Eur J Neurol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"Gilhus","year":"2015","journal-title":"Eur J Neurol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.exger.2010.03.007","article-title":"Remodeling of the neuromuscular junction precedes sarcopenia related alterations in myofibers","volume":"45","author":"Deschenes","year":"2010","journal-title":"Exp Gerontol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/(SICI)1097-4598(199609)19:9<1069::AID-MUS1>3.3.CO;2-P","article-title":"AAEM minimonograph #25: single-fiber electromyography","volume":"19","author":"Sanders","year":"1996","journal-title":"Muscle Nerve"},{"key":"B115","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"B116","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","article-title":"Clinical and immunological differences between early and late-onset myasthenia gravis in Japan","volume":"230","author":"Suzuki","year":"2011","journal-title":"J Neuroimmunol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/mus.880150616","article-title":"Diagnostic sensitivity of the laboratory tests in myasthenia gravis","volume":"15","author":"Oh","year":"1992","journal-title":"Muscle Nerve"},{"key":"B119","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/j.crad.2014.01.005","article-title":"Imaging of thymus in myasthenia gravis: from thymic hyperplasia to thymic tumor","volume":"69","author":"Priola","year":"2014","journal-title":"Clin Radiol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/cncr.10226","article-title":"The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients","volume":"94","author":"Okumura","year":"2002","journal-title":"Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review) [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology."},{"key":"B122","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/j.1749-6632.1998.tb11010.x","article-title":"Thymectomy in childhood myasthenia gravis","volume":"841","author":"Seybold","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/ejcts\/ezu352","article-title":"Robotic thymectomy in patients with myasthenia gravis: neurological and surgical outcomes","volume":"48","author":"Keijzers","year":"2015","journal-title":"Eur J Cardiothorac Surg"},{"key":"B124","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMc1611704","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Haran","year":"2016","journal-title":"N Engl J Med"},{"key":"B125","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard JF","year":"2017","journal-title":"Lancet Neurol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard JF","year":"2019","journal-title":"Neurology"},{"key":"B128","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard JF","year":"2021","journal-title":"Lancet Neurol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"B130","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","article-title":"Aging, cellular senescence, and cancer","volume":"75","author":"Campisi","year":"2013","journal-title":"Annu Rev Physiol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Ann Rev Pathol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00401-009-0556-6","article-title":"Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease","volume":"118","author":"Streit","year":"2009","journal-title":"Acta Neuropathol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/jnc.14860","article-title":"Microglia and the aging brain: are senescent microglia the key to neurodegeneration?","volume":"151","author":"Angelova","year":"2019","journal-title":"J Neurochem."},{"key":"B134","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.celrep.2017.12.039","article-title":"The aging astrocyte transcriptome from multiple regions of the mouse","volume":"22","author":"Boisvert","year":"2018","journal-title":"Brain Cell Rep"},{"key":"B135","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1460-9568.2011.07738.x","article-title":"Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype","volume":"34","author":"Salminen","year":"2011","journal-title":"Eur J Neurosci"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13296","article-title":"Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice","author":"Ogrodnik","year":"","journal-title":"Aging Cell. ("},{"key":"B137","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.molmed.2010.03.003","article-title":"Inflammatory networks during cellular senescence: causes and consequences","volume":"16","author":"Freund","year":"2010","journal-title":"Trends Mol Med"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e45069","DOI":"10.1371\/journal.pone.0045069","article-title":"Astrocyte senescence as a component of Alzheimer's disease","volume":"7","author":"Bhat","year":"2012","journal-title":"PLoS ONE"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e12937","DOI":"10.1111\/acel.12937","article-title":"Astrocyte senescence: evidence and significance","volume":"18","author":"Justin","year":"2019","journal-title":"Aging Cell."},{"key":"B140","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/acel.12344","article-title":"The Achilles' heel of senescent cells: from transcriptome to senolytic drugs","volume":"14","author":"Zhu","year":"2015","journal-title":"Aging Cell"},{"key":"B141","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/joim.13141","article-title":"Senolytic drugs: from discovery to translation","volume":"288","author":"Kirkland","year":"2020","journal-title":"J Intern Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"E6301","DOI":"10.1073\/pnas.1515386112","article-title":"JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age","volume":"112","author":"Xu","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43587-025-00994-z","article-title":"Senescent-like border-associated macrophages regulate cognitive aging via migrasome-mediated induction of paracrine senescence in microglia","volume":"5","author":"Hu","year":"2025","journal-title":"Nat Aging"},{"key":"B144","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1007\/s10072-025-08254-z","article-title":"Research progress of chronic fatigue in neurodegenerative diseases","volume":"46","author":"Xia","year":"2025","journal-title":"Neurol Sci"},{"key":"B145","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41467-019-11674-z","article-title":"Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model","volume":"10","author":"Spangenberg","year":"2019","journal-title":"Nat Commun"},{"key":"B146","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1523\/JNEUROSCI.2402-19.2020","article-title":"Microglial depletion with CSF1R inhibitor during chronic phase of experimental traumatic brain injury reduces neurodegeneration and neurological deficits","volume":"40","author":"Henry","year":"2020","journal-title":"J Neurosci."},{"key":"B147","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12974-024-03259-5","article-title":"Transient CSF1R inhibition ameliorates behavioral deficits in Cntnap2 knockout and valproic acid-exposed mouse models of autism","volume":"21","author":"Meng","year":"2024","journal-title":"J Neuroinflamm"},{"key":"B148","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: far beyond an antibiotic","volume":"169","author":"Garrido-Mesa","year":"2013","journal-title":"Br J Pharmacol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrrheum.2017.51","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3389\/fimmu.2018.01510","article-title":"Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system","volume":"9","author":"Kubo","year":"2018","journal-title":"Front Immunol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"650708","DOI":"10.3389\/fimmu.2021.650708","article-title":"Baricitinib ameliorates experimental autoimmune encephalomyelitis by modulating the janus kinase\/signal transducer and activator of transcription signaling pathway","volume":"12","author":"Dang","year":"2021","journal-title":"Front Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"643254","DOI":"10.3389\/fphar.2021.643254","article-title":"Neurodegenerative disease and the NLRP3 inflammasome","volume":"12","author":"Anderson","year":"2012","journal-title":"Front Pharmacol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.bbi.2016.12.014","article-title":"Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-\u03b2 and cognitive function in APP\/PS1 mice","volume":"61","author":"Dempsey","year":"2017","journal-title":"Brain Behav Immun"},{"key":"B156","doi-asserted-by":"publisher","first-page":"137032","DOI":"10.1016\/j.neulet.2022.137032","article-title":"NLRP3 Inflammasome inhibitor MCC950 reduces cerebral ischemia\/reperfusion induced neuronal ferroptosis","volume":"795","author":"Wu","year":"2022","journal-title":"Neurosci Lett"},{"key":"B157","doi-asserted-by":"publisher","first-page":"e13817","DOI":"10.1111\/acel.13817","article-title":"Effect of peripheral cellular senescence on brain aging and cognitive decline","volume":"22","author":"Budamagunta","year":"2023","journal-title":"Aging Cell"},{"key":"B158","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1124\/molpharm.123.000803","article-title":"Pharmacological targeting of senescence with senolytics as a new therapeutic strategy for neurodegeneration","volume":"105","author":"Richardson","year":"2024","journal-title":"Mol Pharmacol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1038\/s41591-023-02543-w","article-title":"Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial","volume":"29","author":"Gonzales","year":"2023","journal-title":"Nat Med"},{"key":"B160","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/ijms26030944","article-title":"Elamipretide: a review of its structure, mechanism of action, and therapeutic potential international","volume":"26","author":"Tung","year":"2025","journal-title":"J Mol Sci"},{"key":"B161","doi-asserted-by":"publisher","first-page":"118056","DOI":"10.1016\/j.biopha.2025.118056","article-title":"Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects","volume":"187","author":"Sabbah","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"B162","doi-asserted-by":"publisher","first-page":"747901","DOI":"10.3389\/fnint.2021.747901","article-title":"Neuroprotective effects of a small mitochondrially-targeted tetrapeptide elamipretide in neurodegeneration","volume":"15","author":"Nhu","year":"2021","journal-title":"Front Integr Neurosci"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/antiox13121527","article-title":"Nrf2-independent anti-inflammatory effects of dimethyl fumarate: challenges and prospects in developing electrophilic Nrf2 activators for neurodegenerative diseases","volume":"13","author":"Izumi","year":"2024","journal-title":"Antioxidants."},{"key":"B164","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","article-title":"Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases","volume":"18","author":"Cuadrado","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B165","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neuroscience.2024.02.021","article-title":"Neurometabolic and brain functional alterations associated with cognitive impairment in patients with myasthenia gravis: a combined 1 H-MRS and fMRI study","volume":"544","author":"Zhou","year":"2024","journal-title":"Neuroscience"},{"key":"B166","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","article-title":"Role of the innate and adaptive immune responses in the course of multiple sclerosis","volume":"14","author":"Hemmer","year":"2015","journal-title":"Lancet Neurol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/nature09160","article-title":"Activity-dependent relocation of the axon initial segment fine-tunes neuronal excitability","volume":"465","author":"Grubb","year":"2010","journal-title":"Nature"},{"key":"B168","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1002\/acn3.52182","article-title":"Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy","volume":"11","author":"Waede","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"B170","doi-asserted-by":"publisher","first-page":"e230397","DOI":"10.1148\/radiol.230397","article-title":"Microglial activation imaging using 18F-DPA-714 PET\/MRI for detecting autoimmune encephalitis","volume":"310","author":"Zhang","year":"2024","journal-title":"Radiology"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/brain\/awz144","article-title":"Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines","volume":"142","author":"Filippi","year":"2019","journal-title":"Brain"},{"key":"B172","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.neuropharm.2017.10.034","article-title":"MRI measurements of blood-brain barrier function in dementia: a review of recent studies","volume":"134","author":"Raja","year":"2018","journal-title":"Neuropharmacology"},{"key":"B173","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1148\/radiol.13130531","article-title":"Clinical proton MR spectroscopy in central nervous system disorders","volume":"270","author":"Oz","year":"2014","journal-title":"Radiology"},{"key":"B174","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15252\/emmm.201506123","article-title":"sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers","volume":"8","author":"Su\u00e1rez-Calvet","year":"2016","journal-title":"EMBO Mol Med"},{"key":"B176","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","article-title":"Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study","volume":"40","author":"Justice","year":"2019","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1746161\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:19:42Z","timestamp":1777609182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1746161\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":176,"alternative-id":["10.3389\/fmed.2026.1746161"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1746161","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1746161"}}